For research use only. Not for therapeutic Use.
Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of VEGFR2 activation in endothelial cells[1]. Isolinderalactone suppresses the expression of B-cell lymphoma 2 (Bcl-2), survi
| Catalog Number | I044945 |
| CAS Number | 957-66-4 |
| Synonyms | (3aS,4R,8bR)-4-ethenyl-4,8-dimethyl-3-methylidene-5,8b-dihydro-3aH-furo[2,3-e][1]benzofuran-2-one |
| Molecular Formula | C15H16O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H16O3/c1-5-15(4)6-10-11(8(2)7-17-10)13-12(15)9(3)14(16)18-13/h5,7,12-13H,1,3,6H2,2,4H3/t12-,13-,15-/m0/s1 |
| InChIKey | VXZIFOKTSURLNL-YDHLFZDLSA-N |
| SMILES | CC1=COC2=C1C3C(C(=C)C(=O)O3)C(C2)(C)C=C |
| Reference | [1]. Park JH, et al. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. Cancer Lett. 2020;478:71-81. [2]. Hwang JY, et al. Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model. Cancer Lett. 2019;443:25-33. |
